Abstract:B2 Background: NSCLC patients carrying the somatic mutation of epidermal growth factor receptor (EGFR) has been shown to be hyperresponsive to the EGFR tyrosine kinase inhibitor Gefitinib and Erlotinib. The most common NSCLC associated EGFR mutations are the in-frame deletion in exon 19 (E746_A750del) and the point mutation in exon 21 (L858R), accounting for 85-90% EGFR mutations. The ability to detect mutated gene products in cancer cells can identify patients most likely benefit from such therapies.  Methods: We generated rabbit monoclonal antibodies (RmAb) against EGFR with E746-A750 deletions and L858R point mutation. We tested the antibodies by Western blot, Immunofluorescence (IF) and Immunohistochemistry (IHC). In addition, we tested these antibodies on 40 molecularly pre-typed tumors by IHC. Finally, we used a panel of four antibodies (two mutant antibodies, a total EGFR antibody, and a pan-keratin antibody) to screen 340 cases of tumor samples with unknown genotype by IHC.  Results: The results from Western blot, IF, and IHC confirmed that these antibodies could specifically detect the mutant EGFR proteins. IHC data from 40 molecular pre-typed samples perfectly matched the result from DNA sequencing. In those 340 cases of tumor samples, 28 cases were stained positive by L858R antibody and 24 cases were stained positive by EGFR deletion antibody. The positive rate by both antibodies is 15.3%. The DNA from all IHC positive samples and negative adenocarcinoma samples were sent for DNA sequencing. The sensitivity of these mutant specific antibodies is 92.5% and the specificity is 95.8%. In addition, some tumor samples positive for EGFR mutation by IHC and Mass Spec based DNA sequencing were negative by direct DNA sequencing due to low percentage of cancer cells.  Conclusions: The IHC combined mutant EGFR specific antibodies and total EGFR antibody can be used to detect the EGFR mutations and measure the expression level of total EGFR protein in tumors. In addition, this assay enables us to examine paraffin blocks from small biopsy samples, which are difficult to extract enough high quality DNA for sequencing. This IHC assay has the potential to be developed for use to screen lung cancer patients for the treatment with EGFR kinase inhibitors in a clinical setting.

Molecular diagnosis and individual target therapy: Detecting EGFR mutations in NSCLC by immunohistochemistry with antibodies

Detection of Egfr Mutations with Mutation-Specific Antibodies in Primary Lesions of Non-Small Cell Lung Cancer

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Immunohistochemical Detection of Mutations in the Epidermal Growth Factor Receptor Gene in Lung Adenocarcinomas Using Mutation-Specific Antibodies.

Detection of EGFR gene mutations with mutation-speciifc immunohistochemistry in non-small cell lung cancer

Comparison of Cross-Platform Technologies for EGFR T790M Testing in Patients with Non-Small Cell Lung Cancer

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Detection and Dynamic Changes of Egfr Mutations from Circulating Tumor Dna As A Predictor of Survival Outcomes in Nsclc Patients Treated with First-Line Intercalated Erlotinib and Chemotherapy

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Simple and sensitive method for detecting point mutations of epidermal growth factor receptor using cationic conjugated polymers.

Detection Of Egfr Mutations Of Serum Circulating Dna

Immunostaining with EGFR Mutation–specific Antibodies: a Reliable Screening Method for Lung Adenocarcinomas Harboring EGFR Mutation in Biopsy and Resection Samples

Detection Of' Epidermal Growth Factor Receptor Mutations In Plasma By Mutant-Enriched Pcr Assay For Prediction Of The Response To Gefitinib In Patients With Non-Small-Celi Lung Cancer

High Feasibility of Liquid-Based Cytological Samples for Detection of EGFR Mutations in Chinese Patients with NSCLC.

EGF Receptor Testing for Non‐Small Cell Lung Carcinomas

Establishment of multiplex allele-specific blocker PCR for enrichment and detection of 4 common EGFR mutations in non-small cell lung cancer

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

Development and Clinical Application of Liquid Chip Luminex Assay in Thedetection of Epidermal Growth Factor Receptor and K-Ras Mutation

Egfr Mutation Status In Plasma And Tumor Tissues In Non-Small Cell Lung Cancer Serves As A Predictor Of Response To Egfr-Tki Treatment